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Abstract
Background: Mutations in FLT3 result in activated tyrosine kinase activity, cell growth stimulation, and a poor
prognosis among various subtypes of leukemia. The causes and timing of the mutations are not currently known.
We evaluated the prevalence and timing of origin of FLT3 mutations in a population series of childhood leukemia
patients from Northern California.
Methods: We screened and sequenced FLT3 mutations (point mutations and internal tandem duplications, ITDs)
among 517 childhood leukemia patients, and assessed whether these mutations occurred before or after birth
using sensitive “backtracking” methods.
Results: We determined a mutation prevalence of 9 of 73 acute myeloid leukemias (AMLs, 12%) and 9 of 441
acute lymphocytic leukemias (ALLs, 2%). Among AMLs, FLT3 mutations were more common in older patients, and
among ALLs, FLT3 mutations were more common in patients with high hyperdiploidy (3.7%) than those without
this cytogenetic feature (1.4%). Five FLT3 ITDs, one deletion mutation, and 3 point mutations were assessed for
their presence in neonatal Guthrie spots using sensitive real-time PCR techniques, and no patients were found to
harbor FLT3 mutations at birth.
Conclusions: FLT3 mutations were not common in our population-based patient series in California, and patients
who harbor FLT3 mutations most likely acquire them after they are born.
Background
Certain, but not all, chromosome translocations in
childhood leukemia are known to be present at birth.
This phenomenon of prenatal origin was initially pre-
sumed from twin studies where it was observed that
mono-amniotic twins always harbored the same translo-
cations (reviewed in [1]). In addition, several studies
have shown that specific mutations found at diagnosis
in children with leukemia were present at birth, that is,
“backtracked” to neonatal Guthrie Cards (blood spots
used for newborn screens) (reviewed in [2]). The MLL
rearrangement in infant ALL “backtracks” in nearly all
cases and TEL-AML1 is found on 75% of Guthrie cards
matched to leukemia cases with the translocation [3-5].
The E2A-PBX1 fusion generated by the t(1;19) translo-
cation is a likely exception, with a postnatal origin [6],
along with possibly others. These results collectively
support a “two hit” model of leukemia, with one hit
e a r l yi nl i f eo rin utero,a n da n o t h e ra tal a t e rd a t ei n
temporal proximity to leukemia diagnosis.
The FLT3 gene is located on chromosome 13q12 and
encodes a Type III membrane receptor kinase that regu-
lates normal hematopoiesis. Mutations in FLT3 in AML
occur in approximately 5-15% in children and 25-35% in
adults, and account for the most common single gene
defect in AML (reviewed in [7]). Several studies have
indicated that children and adults with AML and the
FLT3 mutation have a very poor prognosis. FLT3 muta-
tions have also been documented in adult and pediatric
ALL. An initial report demonstrated a 14% frequency of
FLT3 mutations among childhood ALL overall, with
mutations concentrated among the cytogenetic sub-
groups high hyperdiploidy (> 50 chromosomes in diag-
nostic karyotype) and MLL-translocation [8]; more
recent studies have indicated a lower overall frequency
in childhood ALL (in the 1-8% range) while consistently
demonstrating a higher incidence among those with
MLL rearrangement and high hyperdiploidy [9-13]. The
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mia is of interest in part because of the existence of sev-
eral promising FLT3 inhibitors currently under
development (reviewed in [14]) such inhibitors are more
effective in the presence of FLT3 activation.
Internal Tandem Duplications (ITDs) and activation
loop mutations are two unique FLT3 mutations that
have been characterized. ITDs, which occur on exon 14,
are insertions of repeated base pairs that range from 3-
400 base pairs each. Activating loop mutations occur on
exon 20; they are most commonly missense point muta-
tions that occur at codon 835/836. Point mutations at
codon 840, 841 and 842 have been described as well as
insertion of base pairs between codons 841 and 842. In
adult AML, ITDs comprise the majority of mutations,
while in pediatric AML, ITD mutations are less com-
mon. It has been proposed that FLT3 mutation may be
a late event in leukemia, given that FLT3 mutation sta-
tus are often changed between paired diagnosis and
relapse of adult and childhood patients with AML
[15-17] or ALL [18]. The present study was conducted
to formally assess this timing. We screened a large
population case series of pediatric leukemia for FLT3
mutations of both types and determined whether FLT3
ITD mutations were present at birth by examining DNA
on the corresponding Guthrie cards.
Methods
The research presented here was reviewed and approved
by the UCSF Committee on Human Research, protocol
# H10806-17300-12, and all study personnel completed
appropriate human subjects training courses. Research
material was derived from the Northern California
Childhood Leukemia Study (NCCLS), and epidemiology
study based at UC Berkeley.
Patients
The patient population consisted of 517 consecutive leu-
kemia patients enrolled in the 9 hospitals participating
in the NCCLS during the years 1995 to 2002. Intensive
cytogenetic, morphologic, and flow cytometry review
[19], parental interviews [20,21] and biologic and envir-
onmental sampling [22] were performed, as well as
characterization of NRAS and KRAS mutations [23]. A
detailed description of this approximately population-
based study design can be found elsewhere [24]. Paren-
tal demographic characteristics were provided by the
case mother (97.5%) or father (2.5%) through in-person
interviews in the home of the parents. A full cytopatho-
logical review to distinguish immunophenotype and
cytogenetic characteristics was instituted as previously
described [19,23]. We employed fluorescence in situ
hybridization (FISH) to further assess status of two
major but cryptic cytogenetic subtypes of childhood
ALL, TEL-AML1 translocation and high hyperdiploidy,
using combined gene-loci specific FISH probes for chro-
mosomes 12 (TEL)a n d2 1( AML1), as well as centro-
mere probe for chromosome X. Because > 96% of high
hyperdiploid patients have extra copies of both chromo-
somes 21 and X in the same cell [25,26], cases with
both extra X and 21 were classified as high hyperdi-
ploidy in the current study. For comparisons with
healthy children, controls were individually matched by
birthdate, gender, race and ethnicity to cases, and uti-
lized the same questionnaire.
Mutation Screening
Each sample was amplified by PCR at the two most
common sites for the FLT3 mutation using Optimase
DNA polymerase (Transgenomics) with standard meth-
o d s .T h ef o l l o w i n gp r i m e r sw e r eu s e dt oa m p l i f ye x o n
14-15 where the ITD mutation occurs and exon 20
where missense point mutations commonly occur: ITD-
F TATCTGCAGAACTGCCTATTCC, and ITD-R
CTTTCAGCATTTTGACGGCAACC; MUT-F
CTCCTACTGAAGTTGAGTGTAG, and MUT-R
CAGTGAGTGCAGTTGTTTACCA, respectively. Each
PCR product was analyzed on a 3% metaphor agarose
g e lt oc o n f i r mt h ep r e s e n c eo ra b s e n c eo ft h ep r e d i c t e d
amplicon (large ITDs are indicated by an extra band of
larger than expected size). Samples that exhibited ITD
mutation (for exon 14 samples) on agarose gel were
subsequently sequenced. RFLP analysis was used to
screen for missense FLT3 mutations (exon 20). EcoRV
digests wild type FLT3 DNA, but does not digest a
point mutation at the most common mutation site.
Twenty-five μl of the PCR product was digested with 10
Uo fEcoRV for 2 hours at 37°C, followed by incubation
at 80°C for 20 minutes to inactivate the enzyme. Diges-
tion products were visualized by electrophoresis on a 3%
agarose gel. Positive samples were gel extracted with the
Qiagen QIAquick Gel Extraction Kit and confirmed
with sequencing. All PCR products were also analyzed
on denaturing high pressure liquid chromatography
(DHPLC) using a Varian Wave machine with a Transge-
nomics column at 57.5C; and suspect mutations indi-
cated by aberrant wave patterns were sequenced. This
permitted the discovery of mutations outside of codon
835.
Backtracking
ITD-junction primers that would bind the mutant and
would not bind wild type DNA were specifically
designed for each mutant. Patient- and mutant-specific
primers were designed for each FLT3 ITD mutation.
The specificity of each mutant specific primer was tested
by performing PCR amplifying diluted mutant DNA
from a patient in limited dilutions (1:10) within wild
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primers will not bind wild type DNA with optimized
assays. This dilution series was used to assess the sensi-
tivity of the assay each time the assay was performed.
SYBR green PCR was performed using the mutant spe-
cific primer pair designed for each patient to amplify
DNA on the diagnostic DNA dilution series and the
corresponding Guthrie card for each patient sample
where a FLT3 ITD mutation was identified.
For point mutation backtracking, we used methods
modified from our previous experiments with KRAS2
mutation backtracking [27]. Dilution series of patient
DNA diluted into wild-type DNA (from peripheral
blood cells) was used to assess assay sensitivity each
time the assay was performed. Guthrie card DNA (240
ng) and dilution series of diagnostic DNA from each
patient diluted into normal DNA were digested with 5
units EcoRV for 16 hours in 10 ul. An additional 5 units
of EcoRV was added for 2 more hours (18 hours total).
The sample was split into six for subsequent PCR analy-
sis (40 ng per reaction). PCR primers D835-BTF
(ACATCACAGTAAATAACACTCTGGTG) and D835-
BTR (GACACAACACAAAATAGCCGTAT) were used
for the SYBR Green PCR backtracking. Nontemplate
controls as well as wild-type DNA controls were run
alongside patient dilution series and Guthrie DNAs.
For both ITD and point mutations, we utilized SYBR
green PCR on an ABI 7900HT with 384 well block:
Reactions were performed with 1× buffer (SYBR Green
PCR Core Reagents, ABI), 1× AccuPrime PCR buffer,
300 nM of each primer, the appropriate patient-specific
forward primer and ITD-R2 (for the ITD reactions) and
3% DMSO, 0.4 U AccuPrime Taq DNA polymerase
(Invitrogen), 40 ng template DNA, and water to yield a
10 ul reaction volume. Reactions were performed at 95°
C for 5 min, followed by 50 cycles of 94°C for 15 sec,
and 60°C for 15 sec. Backtracking PCR reactions were
set-up in a different room of the research facility with
separately stored PCR reagents from the laboratory
where patient DNA was stored and processed for muta-
tion screening, to prevent back-contamination. Test
reactions with primers to ACTB (beta-actin) were routi-
nely used to confirm the suitability of Guthrie DNA for
PCR amplification.
Results
Eighteen FLT3 mutations were discovered among 517
acute leukemia cases for an overall frequency of 3.5%.
Nine of 73 were found in AML (12.3% frequency) and
9/441 among ALL patients (2.0%). FLT3 mutations were
as common in AML-M2 subtype (3 of 20 AML-M2
patients) as in other subtypes (6 of 40 non-AML-M2
patients). Regarding mutation type, insertion/deletion
(indel) mutations were more common among AML
patients (6 of the 9 indel mutations) than ALL patients
(3 of the 9 indels, Table 1). All patients were concur-
rently assessed for NRAS and KRAS codon 12 and 13
mutations; one ALL patient had a concurrent KRAS
mutation with FLT3 but no other patients were concur-
rent for these mutations (Table 1). AML patients with
FLT3 mutations were older than those without muta-
tions (average 11.5 yrs vs. 7.3 yrs, P = 0.01 by t-test);
ALL patients with FLT3 were slightly but not signifi-
cantly older (6.4 vs. 5.5 years average, P = 0.4, t-test).
Our observation that indel mutations were more com-
mon among AMLs while point mutations were more
common among ALLs, suggests a potential complemen-
tation or selection of mutation type with cell lineage.
Five high hyperdiploid patients had FLT3 mutations
among 132 in our cases series (3.7%), and four FLT3
mutations among 309 non-high hyperdiploid ALLs
(1.3%) indicating some bias towards high hyperdiploidy
though not significantly (P = 0.13, Fisher’s exact test).
Eight indel mutations were identified consisting of 8
internal tandem duplications and 1 unconventional dele-
tion. All indel mutants occurred in a 102 base pair
region within exon 14 of the FLT3 gene, except for one
case (0126) whose duplication included one base in the
intronic region between exon 14 and 15 (Figure 1 and
Additional File 1, Figure S1). Indels ranged from a 9
base pair deletion to a 90 base pair insertion and all pre-
served the open reading frame. Of the 9 indel mutations
found, 6 Guthrie cards were available for backtracking.
Each of these 6 Guthrie cards was used with their
respective mutant specific primers (Table 2) in an
attempt to amplify the DNA and determine if the muta-
tion was present in the birth blood. None of the DNA
from the 6 Guthrie cards DNA was amplified using the
mutant specific primers at a sensitivity of 1 cell per
6,700 tested in 40 ng DNA (1.5 × 10
-4)s u g g e s t i n gt h a t
the indel mutations were either not present in the DNA
from the Guthrie cards, or were present but at a lower
frequency than detectable by our assay.
Nine point mutations in the FLT3 gene were identified
with 8 located at codon 835 and 1 located at codon 842.
The latter was discovered using Denaturing High Pres-
sure Liquid Chromatography (DHPLC) while the
remaining by PCR-RFLP; all were sequenced for confir-
mation. One patient exhibited two mutations in codon
835 (patient #0803, Table 1). We cloned the PCR pro-
duct using TA cloning kit (Invitrogen) and sequenced 8
clones - the mutations were present on opposite alleles
meaning that two oncogenic mutations existed in this
patient. Guthrie cards were available for 4 of these
patients, and backtracking experiments were successfully
performed on 3 patients at a similar sensitivity as the
indel mutations (1 cell in 40 ng DNA), and the three
patients were negative for mutant sequence. The
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Page 3 of 7Table 1 FLT3 mutations among 517 acute leukemia subjects from the Northern California Childhood Leukemia Study
Patient
ID
ITD or
MUT*
MUT Age Cytogenetics FAB
(lineage)
Backtrack
result
†
0004 ITD 6.1 46, XY [10/20]; 46, XY, del(9)(p13) [9/20]; 47, XY, +?22 [1/20] ALL neg
0087 ITD 10.5 46, XY [21/24] AML-M1 neg
0104 ITD 9.1 46, XY [19/20]; 44, XY, -14, -22 [1/20] ALL-L1
(T-cell)
neg
0126 ITD 14.9 46, XX [20/20] AML-M2
0201 MUT GAT®GAA D835E 13.2 46, XY [20/20] AML-M2
0261 ITD 13.7 46, XX, t(6;9)(p23;q34) [23/24] AML-M2 neg
0544
‡ MUT GAT®GTT D835V 5.3 46, XX [20/20]; nuc ish 12p13(TEL×2), 21q22(AML1×4) [149/207]/12p13
(TEL×2), 21q22(AML×2) [31/207]/12p13(TEL×2), 21q22(AML1×3) [25/207]
ALL neg
0678 ITD 14.5 46, XX [20] AML-M2
0738 MUT TAT®TGT Y842C 5.0 45, XY, -7, del(13)(q13q21) [12/20]; 46, XY [8/20] ALL-L1
0745 MUT GAT®TAT D835Y 12.7 46, XY [21/21]; nuc ish 4cen(CEP4×2),
10cen(CEP10×2), 12p13(TEL×2), 21q22(AML1×2)
ALL-L1/
L2
0796
‡ MUT GAT®TAT D835Y 1.8 46, XY [3/3]; nuc ish 12p13 (TEL×3), 21q22(AML1×4) [90/100], 12p13(TEL×2),
21q22(AML1×2) [10/100] FISH: +12++21/++X (presumed cryptic high
hyperdiploidy)
ALL-L1 neg
0803 MUT GAT®TAT D835Y
and GAT®CAT
D835H
0.3 46, XY [20/20]; nuc ish 11q23 (MLL5’x2, MLL3’x2) [200/200] AML-M5
0945
‡ MUT GAT®TAT D835Y 7.9 46, XY [21/21] ALL neg
0999 ITD 8.3 46, XX [20] AML
1043 MUT GAT®CAT D835H 14.0 46, XY, inv(16)(p12q22) [12/12] AML
1073
‡ DEL 5.9 46, XY [30]; nuc ish 9q34(ABL×2), 22q11.2(BCR×2) ALL neg
1107
‡§ MUT GAT®GCT D835A 3.5 56~58, XY, dup(1)(q21q32),+4,+5,+6,+10,+14,+18,+18,+19,+21, +22,+2mar [5/
23]; 46, XY [18/23]
ALL-L1
1148 ITD 14.5 47, XX, +14 [16] AML neg
ITD, internal tandem duplication; MUT, point mutation; DEL, deletion.
† neg: 240 ng of patient Guthrie card was tested and was determined to be negative. The rest of the patients were not tested.
‡ Patients exhibiting high hyperdiploidy by FISH assay (see Materials and Methods)
§Patient 1107 has a KRAS mutation, which was also negative in backtracking experiment (ref #23)
Figure 1 Relative location and sizes of FLT3 ITD mutations and deletion in 9 patients from the Northern California Childhood
Leukemia Study. Black boxes - regions of duplication; white box - deletion of FLT3 sequence in one patient. * - positions where multiple breaks
occurred.
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ples with available cards was not obtained. In sum,
between indel and point mutation samples, 9 cards were
tested and all were negative for presence of FLT3
mutation.
Discussion
Using NCCLS bone marrow samples, we have screened
for FLT3 mutations in the largest sample of pediatric
leukemias yet reported. Our results confirm the pre-
viously reported occurrence of FLT3 mutations in both
pediatric ALL and AML although the incidence was
lower than that of reported for some previous patient
series. The highest rates of FLT3 mutation were
recorded in population series of leukemias in Japan (9%
of 162 ALL patients) [28] and Sweden, with 8% of ALL
and 21% of AMLs (in children up to age 17 yrs) [9].
Lower frequencies were found in other population series
in Greece (2.3% among 86 ALL patients), the UK (3.5%
of 86 ALL patients), and Japan (1% of ALL 95 patients)
[12]. Our study is the largest FLT3 screen in a pediatric
population, and was performed in a population-based
series of 517 cases. The rate of FLT3 among AML
patients was 12.3%, which may be lower than some
pediatric series since our study includes younger chil-
dren only (< 15 years). The ALL rate of 2.0% found in
here is comparable with the larger more recent reports.
I ti su n l i k e l yt h a tw eh a v em i s s e dp a t h o g e n e t i cFLT3
mutations in exons 11 and 15 since we incorporated a
DHPLC screen of mutations. An additional notable dif-
ference between the current study and other studies is
the apparent lack of a significant association between
high hyperdiploidy and FLT3 mutation among our ALL
patients, although this lack of significance may be due
to small numbers. The association between RAS muta-
tions and high hyperdiploidy is extremely strong in our
patient sample set [29] and therefore we can confirm a
RAS pathway association. It is unclear whether a lower
prevalence of FLT3 mutations among hyperdiploid cases
in California (compared to, for instance Paulsson et al.,
[11]) is due to differences in etiology of this subtype
based on genetic or environmental characteristics of
patients in California.
Our results suggesting that the FLT3 mutation is not
present at birth is consistent with the hypothesis that
FLT3 mutations are a second stage mutation. However,
we cannot rule out that the mutations were present in
some children but at a level beneath the sensitivity of
the assay, or sequestered in the bone marrow and not in
blood circulation. Our results corroborate that of Burja-
nivova, et al., who did not find evidence of prenatal ori-
gin of FLT3 in two AML patients [30]. The “two hit”
model of leukemogenesis related to FLT3 proposed by
Gilliland and Griffin, hypothesizes that two specific
types of mutations are required in leukemia: one muta-
tion that promotes proliferation and another mutation
that stops differentiation [31]. Mutation of FLT3,l i k e
other tyrosine kinases is associated with proliferation
and may complement mutations that impair cell differ-
entiation such as the deletion of B-cell transcription fac-
tors or translocation-associated fusion genes. NRAS
mutations and FLT3 both promote myeloproliferation,
so their presence together is not necessary for leukemo-
genesis. The MLL gene rearrangement blocks differen-
tiation and its association with FLT3 supports this
model as well. None of our FLT3-mutant patients exhib-
ited an MLL, TEL-AML1, AML1-ETO or other common
translocation, so we were unable to examine a transloca-
tion concurrently with FLT3 in a backtracking experi-
ment. However, strong prior evidence that high
hyperdiploidy is a prenatal event [32-35], combined with
no evidence of prenatal origin of FLT3 mutation in five
high hyperdiploid patients here, helps to place FLT3
mutation postnatally.
Conclusions
In conclusion, FLT3 mutations are not common in our
California childhood leukemia population, where RAS
mutations are far more common [29]. Our investigation
provided no evidence that FLT3 mutation occurs before
birth, compatible with a hypothesis of postnatal origin
for these mutations.
Additional material
Additional file 1: Figure S1. FLT3 ITD Sequences in the Northern
California Childhood Leukemia Study. Exact sequences of internal
tandem duplications found in patients from the Northern California
Childhood Leukemia Study.
Table 2 PCR Primers used for FLT3 ITD Backtracking on
Guthrie card DNA: Northern California Childhood
Leukemia Study
Primer Name Primer Sequences
‡ (5’(3’)
ITD-R2 AGACAAATGGTGAGTACGTGCA
ITD-4-F ATATGATCTCtccgagggcc
ITD-87-F TATGAATATGAgTTCAGAGAATATG
ITD-104-F GAGTTTCCcctcgggaag
ITD-261-F AGAGAATATGAGACCGGCTC
ITD-1073-F* GAGTACTTCccCAGAGAATATG
ITD-1148-F AGAGAATATGAgTACGTTGATTTC
‡ bold, WT sequence; underlined, ITD; lower case, N nucleotides
*1073 had an 11 bp deletion with a 2 bp insertion, giving an overall deletion
of 9 bp.
ITD-R2 was used as the reverse primer for all the backtracking reactions.
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